What nobody knows yet.

The longest fetched trial of the fat-loss compound ran 48 weeks. The longest of the growth hormone compound with an approval ran twelve months. Most of the rest ran weeks. Nothing in the entire fetched literature for any compound on this site tells you what three years of use does, because nobody has published three years of use.

That matters most for the compounds people intend to stay on. A 90-day protocol is inside the studied window for the compounds that have one. A decision to keep going after the second or third cycle is a decision made past the edge of the evidence, and it should be made knowing that rather than assuming somebody checked.

Not one trial cited anywhere in this wing recruited a Filipino cohort as its primary population. The closest is a phase 3 diabetes trial that recruited in the United States, Mexico and India. Everything else was run in North America, Europe or Russia.

Body composition, metabolic response and the baseline rate of conditions like diabetes differ across populations, and this one is under-represented in almost all clinical research. Nobody can tell you the effect size in a Filipino body because nobody has measured it. That is a gap in the literature, not a gap in this site's honesty about it.

Every trial in this wing gave one compound, alone, against placebo or against one active comparator. The protocols this site builds run two, three or four compounds together, staged over weeks. There is no published trial of any of those combinations.

This is why the protocols here stage compounds rather than starting them together, and why the stacking rules in the engine are conservative. Sequencing is not a marketing decision; it is the only way to attribute an effect or a side effect to something specific when the literature cannot tell you what a combination does.

The tesamorelin trials were 86% men in the largest fetched study. The growth hormone axis pharmacology was done in healthy men. The NAD+ insulin sensitivity trial was in postmenopausal women, which is a welcome exception and also a specific population rather than a general one.

For people over sixty, the fetched record thins out further outside the disease populations. The compounds most associated with ageing have been studied mostly in middle-aged adults, in people with a condition, or in mice. If you are over sixty and healthy, the literature about you is thinner than the marketing suggests.

The compounds on this site are sold as research material. That is a legal and regulatory category, and what it means practically is that no regulator has assessed the product, approved an indication, or licensed a manufacturer to make it to a standard somebody inspects. There is no marketing authorisation and no pharmacovigilance system collecting reports of what goes wrong.

This site makes no claim about the purity or the testing of anything, anywhere, and the content gate that runs on every build fails if such a claim appears. What we say instead is the true thing: fulfilment is by Primara Labs, our partner and supplier, and the regulatory position is the one described above.

For the repair peptides, the copper tripeptide, the mitochondrial peptide and the anti-inflammatory tripeptide, most of what exists is mechanism: cells moving faster, genes changing expression, mice performing better. Every one of those findings is real. None of them is a trial showing a person got better.

Most compounds that work in mice fail in humans. That is not cynicism, it is the base rate. When a page in this wing says the evidence is preclinical, that is what it means, and it should change what you expect rather than only how you describe it.

Three things, none of which closes the gap. The protocols stage compounds so an effect can be attributed. The medical answers in the quiz remove compounds entirely rather than warning beside them. And every page in this wing carries the trial, the population, the number of participants and the date the record was fetched, so you can weigh it rather than take our word.

The fourth thing is yours: a number written down on day one and compared at day 90. The literature will not tell you what happens to you. Your own baseline will. Take it to a doctor who knows you before you begin.